Pharma & Biotech Global Week in Review 26 Aug 09 from IP Think Tank

Here is IP Think Tank’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: http://thinkipstrategy.com/subscribe/

 
Highlights this week included:

Nexavar (Sorafenib) – India: Delhi High Court rejects Bayer complaint for patent linkage (Intellectual Property Watch) (Spicy IP) (GenericsWeb)

Evista / Xigris – US: CAFC grants en banc request to challenge written description requirement: Ariad v Lilly (Patently-O) (Filewrapper) (Washington State Patent Law Blog) (Patent Docs) (Holman’s Biotech IP Blog) (Patents4Life)

Singulair (Montelukast) – US: Merck get injunction preventing Teva from selling generic Montelukast: Merck Sharp & Dohme Pharmaceuticals SRL v Teva Pharmaceuticals USA (The IP Factor) (IP Watchdog) (SmartBrief) (SmartBrief) (GenericsWeb)

 
General

Patents explained by Medecins Sans Frontieres movie (Innovationpartners)

New book ‘Who Owns You? The Corporate Gold Rush to Patent Your Genes’ perpetuates popular misperceptions surrounding gene patents (Holman’s Biotech IP Blog)

Australian pharmaceutical patent term extension for patches and implants: N V Organon; LTS Lohmann Therapie-Systeme AG and Schwarz Pharma Limited (Patent Baristas)

China: Obama Administration and compulsory licensing in China (China Hearsay)

China: Forty-two of Simcere’s generic drugs enter China’s Essential Drug List (GenericsWeb)

EU: A recent review of the SPC scene (The SPC Blog)

Korea: Will Tamilflu ignite another battle for compulsory license in Korea? (Korea IP Law Blog)

US: Senate Agriculture/FDA Appropriations Bill amendment seeks to streamline development and regulation of products for rare and neglected diseases (FDA Law Blog)

US: Professor Grabowski’s economic analysis of data exclusivity for follow-on biologic drugs (Patent Docs)

US: Follow-on biologics news briefs: President Obama wants to speed up introduction of generic drugs; biosimilars pose ‘limited threat’; Amgen CEO says biologic manufacturers will likely retain market share; PhRMA VP says 12 years of exclusivity is needed (Patent Docs)

US: American Enterprise Institute for Public Policy Research presents follow-on biologic ‘reality’ (Patent Docs)

US: Boehringer Ingelheim Pharma seeks review and correction of patent term adjustment calculation (Patent Docs)

 
Products

Acai berry, Resveratrol – Dr Oz and Oprah sue long list of defendants over unauthorised use of their name, likeness to promote Resveratrol and numerous other dietary supplements, cosmetics and over the counter drugs (The Trademark Blog) (IPKat)

Eloxatin (Oxaliplatin) – US: The Oxaliplatin controversy – a tale of intrigue, secrecy and suspense (FDA Law Blog)

Evista / Xigris – US: CAFC grants en banc request to challenge written description requirement: Ariad v Lilly (Patently-O) (Filewrapper) (Washington State Patent Law Blog) (Patent Docs) (Holman’s Biotech IP Blog) (Patents4Life)

Gemzar (Gemcitabine) – US: District Court for E D Michigan grants Sun Pharma’s motion for partial summary judgment, invalidating Eli Lilly’s method-of-use patent for Gemzar (GenericsWeb)

Malarone (Atovaquone and Proguanil) – US: SmithKline Beecham files patent infringement suit against Glenmark following Para IV challenge (Patent Docs)

Nexavar (Sorafenib) – India: Delhi High Court rejects Bayer complaint for patent linkage (Intellectual Property Watch) (Spicy IP) (GenericsWeb)

Plavix (Clopidogrel) – US: USPTO orders re-examination of Plavix patent (GenericsWeb)

Precision Plus Protein Dual Color Standards – US: Life Technologies files patent infringement suit against Bio-Rad over it manufacture and sale of standard protein products including Precision Plus Protein Dual Color Standards (Patent Docs)

Protonix (Pantoprazole) – US: Nycomed, Wyeth file patent infringement suit against Apotex following Para IV challenge (Patent Docs)

Simponi (Golimumab) – US: Bayer files patent infringement suit against Centocor based on manufacture and sale of Simponi (Patent Docs)

Singulair (Montelukast) – US: A. F. of L. files antitrust suit against Merck, alleging fraudulent procurement of a patent, improper listing of patent in Orange Book (Patent Docs)

Singulair (Montelukast) – US: Merck get injunction preventing Teva from selling generic Montelukast: Merck Sharp & Dohme Pharmaceuticals SRL v Teva Pharmaceuticals USA (The IP Factor) (IP Watchdog) (SmartBrief) (SmartBrief) (GenericsWeb)

 

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: